APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Gastritis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Chronic Gastritis Treatment Market Analysis and Forecast 2026-2032

19 December 2025193 pages

Choose your research edition.

Industry ResearchChronic Gastritis Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Gastritis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chronic Gastritis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Gastritis Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Gastritis Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Chronic Gastritis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Chronic Gastritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Chronic Gastritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Chronic Gastritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Chronic Gastritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Chronic Gastritis Treatment include Alchem International, Cipla, Katsura Chemical, Lupin Ltd, Microbiotix, Perrigo Pharmaceutical, RESONANCE LABORATORIES, ROLABO OUTSOURCING and SAURAV CHEMICALS, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Chronic Gastritis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chronic Gastritis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Chronic Gastritis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chronic Gastritis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chronic Gastritis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Chronic Gastritis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Chronic Gastritis Treatment Segment by Company

Alchem International

Cipla

Katsura Chemical

Lupin Ltd

Microbiotix

Perrigo Pharmaceutical

RESONANCE LABORATORIES

ROLABO OUTSOURCING

SAURAV CHEMICALS

AstraZeneca

Hangzhou Vega

Wuhan Senwayer Century

Chronic Gastritis Treatment Segment by Type

H2 Antagonists

Antacids

Proton Pump Inhibitors

Others

Chronic Gastritis Treatment Segment by Application

Drug Stimulate

Stress

Irritant

Virus Infection

Others

Chronic Gastritis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Gastritis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Gastritis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Gastritis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Chronic Gastritis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Chronic Gastritis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Gastritis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chronic Gastritis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. H2 Antagonists Major Player Table 3. Antacids Major Player Table 4. Proton Pump Inhibitors Major Player Table 5. Others Major Player Table 6. Global Chronic Gastritis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Drug Stimulate Major Player Table 8. Stress Major Player Table 9. Irritant Major Player Table 10. Virus Infection Major Player Table 11. Others Major Player Table 12. Chronic Gastritis Treatment Industry Trends Table 13. Chronic Gastritis Treatment Industry Drivers Table 14. Chronic Gastritis Treatment Industry Opportunities and Challenges Table 15. Chronic Gastritis Treatment Industry Restraints Table 16. Global Chronic Gastritis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Chronic Gastritis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Chronic Gastritis Treatment Market Share by Region (2021-2026) Table 19. Global Chronic Gastritis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Chronic Gastritis Treatment Market Share by Region (2027-2032) Table 21. Global Chronic Gastritis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Chronic Gastritis Treatment Revenue Market Share by Players (2021-2026) Table 23. Global Chronic Gastritis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Chronic Gastritis Treatment Key Players Headquarters & Area Served Table 25. Global Chronic Gastritis Treatment Players, Product Type & Application Table 26. Global Chronic Gastritis Treatment Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Chronic Gastritis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Chronic Gastritis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Chronic Gastritis Treatment Revenue Market Share by Type (2021-2026) Table 33. Global Chronic Gastritis Treatment Revenue Market Share by Type (2027-2032) Table 34. Global Chronic Gastritis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Chronic Gastritis Treatment Revenue Market Share by Application (2021-2026) Table 38. Global Chronic Gastritis Treatment Revenue Market Share by Application (2027-2032) Table 39. Alchem International Company Information Table 40. Alchem International Business Overview Table 41. Alchem International Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Alchem International Chronic Gastritis Treatment Product Portfolio Table 43. Alchem International Recent Development Table 44. Cipla Company Information Table 45. Cipla Business Overview Table 46. Cipla Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Cipla Chronic Gastritis Treatment Product Portfolio Table 48. Cipla Recent Development Table 49. Katsura Chemical Company Information Table 50. Katsura Chemical Business Overview Table 51. Katsura Chemical Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Katsura Chemical Chronic Gastritis Treatment Product Portfolio Table 53. Katsura Chemical Recent Development Table 54. Lupin Ltd Company Information Table 55. Lupin Ltd Business Overview Table 56. Lupin Ltd Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Lupin Ltd Chronic Gastritis Treatment Product Portfolio Table 58. Lupin Ltd Recent Development Table 59. Microbiotix Company Information Table 60. Microbiotix Business Overview Table 61. Microbiotix Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Microbiotix Chronic Gastritis Treatment Product Portfolio Table 63. Microbiotix Recent Development Table 64. Perrigo Pharmaceutical Company Information Table 65. Perrigo Pharmaceutical Business Overview Table 66. Perrigo Pharmaceutical Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Perrigo Pharmaceutical Chronic Gastritis Treatment Product Portfolio Table 68. Perrigo Pharmaceutical Recent Development Table 69. RESONANCE LABORATORIES Company Information Table 70. RESONANCE LABORATORIES Business Overview Table 71. RESONANCE LABORATORIES Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. RESONANCE LABORATORIES Chronic Gastritis Treatment Product Portfolio Table 73. RESONANCE LABORATORIES Recent Development Table 74. ROLABO OUTSOURCING Company Information Table 75. ROLABO OUTSOURCING Business Overview Table 76. ROLABO OUTSOURCING Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. ROLABO OUTSOURCING Chronic Gastritis Treatment Product Portfolio Table 78. ROLABO OUTSOURCING Recent Development Table 79. SAURAV CHEMICALS Company Information Table 80. SAURAV CHEMICALS Business Overview Table 81. SAURAV CHEMICALS Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. SAURAV CHEMICALS Chronic Gastritis Treatment Product Portfolio Table 83. SAURAV CHEMICALS Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Chronic Gastritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. AstraZeneca Chronic Gastritis Treatment Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Hangzhou Vega Company Information Table 90. Hangzhou Vega Business Overview Table 91. Hangzhou Vega Chronic Gastritis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Hangzhou Vega Chronic Gastritis Treatment Product Portfolio Table 93. Hangzhou Vega Recent Development Table 94. Wuhan Senwayer Century Company Information Table 95. Wuhan Senwayer Century Business Overview Table 96. Wuhan Senwayer Century Chronic Gastritis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Wuhan Senwayer Century Chronic Gastritis Treatment Product Portfolio Table 98. Wuhan Senwayer Century Recent Development Table 99. North America Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 100. North America Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 101. North America Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Chronic Gastritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 105. North America Chronic Gastritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 106. Europe Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. Europe Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. Europe Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. Europe Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. Europe Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Chronic Gastritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 112. Europe Chronic Gastritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 113. China Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 114. China Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 115. China Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 116. China Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 118. Asia Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 119. Asia Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 120. Asia Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Chronic Gastritis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Chronic Gastritis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 123. Asia Chronic Gastritis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 124. SAMEA Chronic Gastritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 125. SAMEA Chronic Gastritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 126. SAMEA Chronic Gastritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 127. SAMEA Chronic Gastritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 128. SAMEA Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. SAMEA Chronic Gastritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 130. SAMEA Chronic Gastritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Chronic Gastritis Treatment Image Figure 2. Global Chronic Gastritis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Gastritis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. H2 Antagonists Image Figure 5. Antacids Image Figure 6. Proton Pump Inhibitors Image Figure 7. Others Image Figure 8. Global Chronic Gastritis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Chronic Gastritis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Drug Stimulate Image Figure 11. Stress Image Figure 12. Irritant Image Figure 13. Virus Infection Image Figure 14. Others Image Figure 15. Global Chronic Gastritis Treatment Market Size (US$ Million) & (2021-2032) Figure 16. Global Chronic Gastritis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Chronic Gastritis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Chronic Gastritis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Chronic Gastritis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Chronic Gastritis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Chronic Gastritis Treatment Revenue Market Share by Type (2021-2032) Figure 23. Global Chronic Gastritis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Chronic Gastritis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Chronic Gastritis Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America Chronic Gastritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Chronic Gastritis Treatment Revenue Share by Type (2021-2032) Figure 28. North America Chronic Gastritis Treatment Revenue Share by Application (2021-2032) Figure 29. North America Chronic Gastritis Treatment Revenue Share by Country (2021-2032) Figure 30. United States Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Chronic Gastritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Chronic Gastritis Treatment Revenue Share by Type (2021-2032) Figure 35. Europe Chronic Gastritis Treatment Revenue Share by Application (2021-2032) Figure 36. Europe Chronic Gastritis Treatment Revenue Share by Country (2021-2032) Figure 37. Germany Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Chronic Gastritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Chronic Gastritis Treatment Revenue Share by Type (2021-2032) Figure 47. China Chronic Gastritis Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Chronic Gastritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Chronic Gastritis Treatment Revenue Share by Type (2021-2032) Figure 50. Asia Chronic Gastritis Treatment Revenue Share by Application (2021-2032) Figure 51. Asia Chronic Gastritis Treatment Revenue Share by Region (2021-2032) Figure 52. Japan Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Chronic Gastritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Chronic Gastritis Treatment Revenue Share by Type (2021-2032) Figure 60. SAMEA Chronic Gastritis Treatment Revenue Share by Application (2021-2032) Figure 61. SAMEA Chronic Gastritis Treatment Revenue Share by Country (2021-2032) Figure 62. Brazil Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Chronic Gastritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • H2 Antagonists
  • Antacids
  • Proton Pump Inhibitors
  • Others
Applications
  • Drug Stimulate
  • Stress
  • Irritant
  • Virus Infection
  • Others
Companies covered
  • Alchem International
  • Cipla
  • Katsura Chemical
  • Lupin Ltd
  • Microbiotix
  • Perrigo Pharmaceutical
  • RESONANCE LABORATORIES
  • ROLABO OUTSOURCING
  • SAURAV CHEMICALS
  • AstraZeneca
  • Hangzhou Vega
  • Wuhan Senwayer Century

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chronic Gastritis Treatment Market by Type
  3. 1.2.1 Global Chronic Gastritis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 H2 Antagonists
  5. 1.2.3 Antacids
  6. 1.2.4 Proton Pump Inhibitors
  7. 1.2.5 Others
  8. 1.3 Chronic Gastritis Treatment Market by Application
  9. 1.3.1 Global Chronic Gastritis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Drug Stimulate
  11. 1.3.3 Stress
  12. 1.3.4 Irritant
  13. 1.3.5 Virus Infection
  14. 1.3.6 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Chronic Gastritis Treatment Market Dynamics
  1. 2.1 Chronic Gastritis Treatment Industry Trends
  2. 2.2 Chronic Gastritis Treatment Industry Drivers
  3. 2.3 Chronic Gastritis Treatment Industry Opportunities and Challenges
  4. 2.4 Chronic Gastritis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Chronic Gastritis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Chronic Gastritis Treatment Growth Trends by Region
  3. 3.2.1 Global Chronic Gastritis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chronic Gastritis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Chronic Gastritis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Chronic Gastritis Treatment Revenue by Players
  2. 4.1.1 Global Chronic Gastritis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Chronic Gastritis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Chronic Gastritis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chronic Gastritis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Chronic Gastritis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Chronic Gastritis Treatment Players, Product Type & Application
  8. 4.5 Global Chronic Gastritis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Chronic Gastritis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Chronic Gastritis Treatment Tier 1, Tier 2, and Tier 3
5 Chronic Gastritis Treatment Market Size by Type
  1. 5.1 Global Chronic Gastritis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Chronic Gastritis Treatment Revenue Market Share by Type (2021-2032)
6 Chronic Gastritis Treatment Market Size by Application
  1. 6.1 Global Chronic Gastritis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Chronic Gastritis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Chronic Gastritis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alchem International
  2. 7.1.1 Alchem International Company Information
  3. 7.1.2 Alchem International Business Overview
  4. 7.1.3 Alchem International Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alchem International Chronic Gastritis Treatment Product Portfolio
  6. 7.1.5 Alchem International Recent Developments
  7. 7.2 Cipla
  8. 7.2.1 Cipla Company Information
  9. 7.2.2 Cipla Business Overview
  10. 7.2.3 Cipla Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Cipla Chronic Gastritis Treatment Product Portfolio
  12. 7.2.5 Cipla Recent Developments
  13. 7.3 Katsura Chemical
  14. 7.3.1 Katsura Chemical Company Information
  15. 7.3.2 Katsura Chemical Business Overview
  16. 7.3.3 Katsura Chemical Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Katsura Chemical Chronic Gastritis Treatment Product Portfolio
  18. 7.3.5 Katsura Chemical Recent Developments
  19. 7.4 Lupin Ltd
  20. 7.4.1 Lupin Ltd Company Information
  21. 7.4.2 Lupin Ltd Business Overview
  22. 7.4.3 Lupin Ltd Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lupin Ltd Chronic Gastritis Treatment Product Portfolio
  24. 7.4.5 Lupin Ltd Recent Developments
  25. 7.5 Microbiotix
  26. 7.5.1 Microbiotix Company Information
  27. 7.5.2 Microbiotix Business Overview
  28. 7.5.3 Microbiotix Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Microbiotix Chronic Gastritis Treatment Product Portfolio
  30. 7.5.5 Microbiotix Recent Developments
  31. 7.6 Perrigo Pharmaceutical
  32. 7.6.1 Perrigo Pharmaceutical Company Information
  33. 7.6.2 Perrigo Pharmaceutical Business Overview
  34. 7.6.3 Perrigo Pharmaceutical Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Perrigo Pharmaceutical Chronic Gastritis Treatment Product Portfolio
  36. 7.6.5 Perrigo Pharmaceutical Recent Developments
  37. 7.7 RESONANCE LABORATORIES
  38. 7.7.1 RESONANCE LABORATORIES Company Information
  39. 7.7.2 RESONANCE LABORATORIES Business Overview
  40. 7.7.3 RESONANCE LABORATORIES Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 RESONANCE LABORATORIES Chronic Gastritis Treatment Product Portfolio
  42. 7.7.5 RESONANCE LABORATORIES Recent Developments
  43. 7.8 ROLABO OUTSOURCING
  44. 7.8.1 ROLABO OUTSOURCING Company Information
  45. 7.8.2 ROLABO OUTSOURCING Business Overview
  46. 7.8.3 ROLABO OUTSOURCING Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ROLABO OUTSOURCING Chronic Gastritis Treatment Product Portfolio
  48. 7.8.5 ROLABO OUTSOURCING Recent Developments
  49. 7.9 SAURAV CHEMICALS
  50. 7.9.1 SAURAV CHEMICALS Company Information
  51. 7.9.2 SAURAV CHEMICALS Business Overview
  52. 7.9.3 SAURAV CHEMICALS Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 SAURAV CHEMICALS Chronic Gastritis Treatment Product Portfolio
  54. 7.9.5 SAURAV CHEMICALS Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Chronic Gastritis Treatment Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 Hangzhou Vega
  62. 7.11.1 Hangzhou Vega Company Information
  63. 7.11.2 Hangzhou Vega Business Overview
  64. 7.11.3 Hangzhou Vega Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Hangzhou Vega Chronic Gastritis Treatment Product Portfolio
  66. 7.11.5 Hangzhou Vega Recent Developments
  67. 7.12 Wuhan Senwayer Century
  68. 7.12.1 Wuhan Senwayer Century Company Information
  69. 7.12.2 Wuhan Senwayer Century Business Overview
  70. 7.12.3 Wuhan Senwayer Century Chronic Gastritis Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Wuhan Senwayer Century Chronic Gastritis Treatment Product Portfolio
  72. 7.12.5 Wuhan Senwayer Century Recent Developments
8 North America
  1. 8.1 North America Chronic Gastritis Treatment Revenue (2021-2032)
  2. 8.2 North America Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Chronic Gastritis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Chronic Gastritis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Chronic Gastritis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Chronic Gastritis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Chronic Gastritis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Chronic Gastritis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Chronic Gastritis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Chronic Gastritis Treatment Revenue by Country
  11. 8.6.1 North America Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Chronic Gastritis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Chronic Gastritis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Chronic Gastritis Treatment Revenue (2021-2032)
  2. 9.2 Europe Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Chronic Gastritis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Chronic Gastritis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Chronic Gastritis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Chronic Gastritis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Chronic Gastritis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Chronic Gastritis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Chronic Gastritis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Chronic Gastritis Treatment Revenue by Country
  11. 9.6.1 Europe Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Chronic Gastritis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Chronic Gastritis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Chronic Gastritis Treatment Revenue (2021-2032)
  2. 10.2 China Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Chronic Gastritis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Chronic Gastritis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Chronic Gastritis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Chronic Gastritis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Chronic Gastritis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Chronic Gastritis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Chronic Gastritis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chronic Gastritis Treatment Revenue (2021-2032)
  2. 11.2 Asia Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Chronic Gastritis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Chronic Gastritis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Chronic Gastritis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Chronic Gastritis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Chronic Gastritis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Chronic Gastritis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Chronic Gastritis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Chronic Gastritis Treatment Revenue by Country
  11. 11.6.1 Asia Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Chronic Gastritis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Chronic Gastritis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chronic Gastritis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Chronic Gastritis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Chronic Gastritis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Chronic Gastritis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Chronic Gastritis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Chronic Gastritis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Chronic Gastritis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Chronic Gastritis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Chronic Gastritis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Chronic Gastritis Treatment Revenue by Country
  11. 12.6.1 SAMEA Chronic Gastritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Chronic Gastritis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Chronic Gastritis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst